Refractory Systemic Lupus Erythematosus clinical trials

Explore recruiting refractory systemic lupus erythematosus clinical trials.

Recruiting refractory systemic lupus erythematosus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Systemic Lupus Erythematosus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients with Severe, Refractory Systemic Lupus Erythematosus

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

MB-CART19.1 in refractory SLE

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).

Spain, France, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, open-label study to evaluate the efficacy and safety of rapcabtagene autoleucel in patients with active, refractory systemic lupus erythematosus (SLE), or active, refractory lupus nephritis (LN).

France, Spain, Italy, Netherlands, Germany, Czechia +7 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE LUPUS NEPHRITIS

Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Refractory Systemic Lupus Erythematosus trials by city

Refractory Systemic Lupus Erythematosus in Toronto Refractory Systemic Lupus Erythematosus in Vancouver Refractory Systemic Lupus Erythematosus in Montreal Refractory Systemic Lupus Erythematosus in Calgary Refractory Systemic Lupus Erythematosus in Edmonton Refractory Systemic Lupus Erythematosus in Ottawa Refractory Systemic Lupus Erythematosus in Winnipeg Refractory Systemic Lupus Erythematosus in Quebec City Refractory Systemic Lupus Erythematosus in Hamilton Refractory Systemic Lupus Erythematosus in Kitchener Refractory Systemic Lupus Erythematosus in London Refractory Systemic Lupus Erythematosus in Halifax Refractory Systemic Lupus Erythematosus in New York Refractory Systemic Lupus Erythematosus in Los Angeles Refractory Systemic Lupus Erythematosus in Chicago Refractory Systemic Lupus Erythematosus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease